Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Merkel Cell (approved 2023)
Astrocytoma (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma, Merkel Cell (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Head and Neck Neoplasms (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)
Malignant Carcinoid Syndrome (Phase 2)
Melanoma (Phase 1/Phase 2)
Mutation (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 3)
Neuroendocrine Tumors (Phase 2)
Oligodendroglioma (Phase 2)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Rectal Neoplasms (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2/Phase 3)
Stomach Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue